Andere Sprachen Gabather AB

Aktien

A2JGN2

SE0010869552

GABA

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:22:02 17.05.2024			% 5 Tage	% 1. Jan.
1,815 ^SEK	-11,89 %		-17,87 %	+28,72 %

10.04.	Gabather AB schließt sich mit dem Zentrum für neuropsychiatrische Schizophrenieforschung in Dänemark zusammen, um eine klinische Phase-II-Studie mit GT-002 durchzuführen	CI
18.03.	Gabather AB reicht zwei neue Patentanträge ein, um neue Erkenntnisse über die Wirkung von GT-002 bei der Behandlung neuropsychiatrischer Störungen zu sichern	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002	10.04.
Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	10.04.
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders	18.03.
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders	18.03.
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders	18.03.
Gabather reports initial positive results from the EEG/fMRI target engagement study	07.03.
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study	07.03.
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29.02.
Gabather AB receives initial EEG data analysis from the GT-002 target engagement study	22.12.
Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)	14.12.
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002	14.12.
Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG	11.12.
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27.11.
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12.10.23
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12.10.23
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17.08.23
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023	11.05.23
Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957	13.04.23
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application	13.04.23
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	08.02.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Gabather AB

Aktien

A2JGN2

SE0010869552

GABA

Andere Sprachen

Filter